This is a summary of the results from two clinical studies of treatment for men with severe hemophilia A or B. The studies were published in the British Journal of Haematology. People with hemophilia either have low amounts of clotting factors or are missing certain clotting factors in their blood. The severity of hemophilia is found out by a blood test. There are medicines that people with hemophilia can take to replace the missing clotting factor. However, sometimes the body thinks the clotting factor used to treat hemophilia is a foreign substance and produces antibodies to destroy it (called inhibitors) which may slow down or stop blood clottingThis Plain Language Summary of Publication article in Future Rare Diseases describes the results from two studies that looked at the treatment for men with severe hemophilia A or B. The study specifically looked at the effectiveness and safety of a medicine called marstacimab.

Please visit Future Medicine using the link to read the article.

The original articles on which this summary is based were both published in the British Journal of Haematology. 

  •  ‘A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia’. Please visit Wiley Online Library using the link to read the article.
  • ‘Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results’. Please visit Wiley Online Library using the link to read the article.